[THE EFFECTIVENESS OF ERADICATION IN PATIENTS WITH PEPTIC ULCER DISEASE ASSOCIATED WITH HELICOBACTER PYLORI, DEPENDING ON THE GENOTYPE OF THE DRUGMETABOLISM OF PROTON PUMP INHIBITORS]

Eksp Klin Gastroenterol. 2015:(3):31-3.
[Article in Russian]

Abstract

One of the most likely causes of the lack of effectiveness of eradication therapy of peptic ulcer associated with Helicobacter pylori, is a feature of omeprazole metabolism by cytochrome CYP2C19. The paper work presents evidence that the rate of reduction of the clinical picture and the likelihood of scarring ulcers and eradication rates higher in patients slow metabolizers of omeprazole.

MeSH terms

  • Cytochrome P-450 CYP2C19* / genetics
  • Cytochrome P-450 CYP2C19* / metabolism
  • Female
  • Genotype*
  • Helicobacter Infections* / drug therapy
  • Helicobacter Infections* / enzymology
  • Helicobacter Infections* / genetics
  • Helicobacter pylori*
  • Humans
  • Male
  • Middle Aged
  • Omeprazole* / administration & dosage
  • Omeprazole* / pharmacokinetics
  • Peptic Ulcer / drug therapy
  • Peptic Ulcer / enzymology
  • Peptic Ulcer / genetics
  • Peptic Ulcer / microbiology
  • Proton Pump Inhibitors* / administration & dosage
  • Proton Pump Inhibitors* / pharmacokinetics

Substances

  • Proton Pump Inhibitors
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Omeprazole